CD4 and neoplasm: A small number of studies with murine cancers (14–18) had already identified the epitopes recognized by CD8+ and CD4+ T cells that were mutated in cancers and were thus cancer specific (Table 1); indeed, one could immunize mice with these peptides and elicit tumor rejection.